| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5026
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5047 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-554 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-554
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50 |
| filingDate |
2000-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2005-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ffaa0ca4c413edaa2655813af611b2f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34340365a97315ff013a0a10aa77ad50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8bbddef484a4350bb5aed492a0cb67af |
| publicationDate |
2005-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1173205-B1 |
| titleOfInvention |
An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport |
| abstract |
An oral pharmaceutical formulation comprising an inhibitor compound of the ileal bile acid transport (IBAT inhibitor compound) and a therapeutically acceptable carrier characterised in that the formulation is designed to deliver the IBAT inhibitor compound in the ileum. The IBAT inhibitor compound can also be administered in combination with a bile acid binder to alleviate possible side effects of therapy with IBAT inhibitor compound, such as for instance diarrhoea. The bile acid binder may be formulated for colon release. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11260053-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10251880-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10188646-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10555950-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11773071-B2 |
| priorityDate |
1999-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |